"DNA Polymerase II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA-dependent DNA polymerase characterized in E. coli and other lower organisms. It may be present in higher organisms and has an intrinsic molecular activity only 5% of that of DNA Polymerase I. This polymerase has 3'-5' exonuclease activity, is effective only on duplex DNA with gaps or single-strand ends of less than 100 nucleotides as template, and is inhibited by sulfhydryl reagents. EC 2.7.7.7.
| Descriptor ID |
D004257
|
| MeSH Number(s) |
D08.811.913.696.445.308.300.230
|
| Concept/Terms |
DNA Polymerase II- DNA Polymerase II
- DNA Polymerase epsilon
- DNA-Dependent DNA Polymerase II
- DNA Dependent DNA Polymerase II
- DNA Pol II
|
Below are MeSH descriptors whose meaning is more general than "DNA Polymerase II".
Below are MeSH descriptors whose meaning is more specific than "DNA Polymerase II".
This graph shows the total number of publications written about "DNA Polymerase II" by people in this website by year, and whether "DNA Polymerase II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Polymerase II" by people in Profiles.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul; 35(7):643-655.
-
Detection and characterization of constitutive replication origins defined by DNA polymerase epsilon. BMC Biol. 2023 02 24; 21(1):41.
-
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol. 2022 02; 6:e2100267.
-
Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Cold Spring Harb Mol Case Stud. 2019 10; 5(5).
-
DNA Polymerase Epsilon Deficiency Causes IMAGe Syndrome with Variable Immunodeficiency. Am J Hum Genet. 2018 12 06; 103(6):1038-1044.
-
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 2018 04 09; 33(4):721-735.e8.
-
POLE mutations in colorectal cancer: a new biomarker? Lancet Gastroenterol Hepatol. 2016 11; 1(3):176-177.
-
Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro Oncol. 2015 Oct; 17(10):1356-64.
-
Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 2014 Nov; 24(11):1740-50.